@FierceMedDev: Israeli team advances genetic device to perform DNA diagnosis. Report | Follow @FierceMedDev
@MarkHFierce: Indiana offers a way to work around the device tax, rather than focusing on repealing it. More | Follow @MarkHFierce
@DamianFierce: Pfizer's ongoing R&D slash and burn could be good news for CROs. Story | Follow @DamianFierce
> A former Lazard banker will be starting a debt fund in Europe to invest in medical technology, diagnostics and life sciences companies. Story
> Smith & Nephew ($SNN) CEO Olivier Bohuon now denies an earlier company statement blaming planned layoffs on the U.S. medical device industry tax. Item
> Ampio Pharmaceuticals ($AMPE) has launched a subsidiary, Luoxis Diagnostics, an in-vitro Dx company that will market the Oxidation Reduction Potential platform. More
> Life Technologies ($LIFE) picked up FDA clearance for its 3500 Dx Genetic Analyzers and SeCore HLA typing kits, designed to determine compatibility between tissue donors. News
> Australia diagnostic company Cellmid will license its anti-midkine diagnostic antibodies to Japan's Fujikura Kasei Co., a major supplier of latex particles used in medical diagnostics. Release
> Planmed Oy won FDA clearance for Verity, a device designed to detect subtle extremity fractures. Item
> Vexim is launching a U.K. subsidiary to expand market reach for its minimally invasive treatment of vertebral fractures. Release
Biotech News
@FierceBiotech: Sanofi move to acquire more shares of Regeneron triggers market buzz. Report | Follow @FierceBiotech
@JohnCFierce: Tresiba news underscores how high the FDA sets the bar on diabetes. Hard for biotechs to play in a field like this. News | Follow @JohnCFierce
@RyanMFierce: 'Mercenary' coders crowd-sourced for immunology research software. Report | Follow @RyanMFierce
> Bayer hands off FDA app as pulmonary hypertension drug race heats up. Story
> Spurning panel endorsement, FDA rejects Novo's long-acting insulin Tresiba. Article
Pharma News
@FiercePharma: Corks pop at Sanofi as FDA nixes Novo's Lantus challenger. Article | Follow @FiercePharma
@EricPFierce: New Celgene drug for multiple myeloma expected to help fuel expansion of market to $7.2 billion. News | Follow @EricPFierce
@AlisonBFierce: A genetically modified smallpox vaccine shrunk tumors in liver cancer patients and extended survival more than a year. More | Follow @AlisonBFierce
> FDA hearing on opioids reflects evolving view on painkiller use. Report
> Will NIH data win Avastin a new use in cervical cancer? Story
CRO News
> GSK ups the ante for trial transparency. Story
> Struggling Cardiome recruits Quintiles to handle heart drug. More
> Struggling Cardiome recruits Quintiles to handle heart drug. News
> QPS snags Florida trial site amid buying spree. Report
> Pfizer's Singapore slash and burn could be good news for CROs. Article
Biotech IT News
> Trials software outfit BioClinica reports annual results (for the last time?) Item
> Sanofi backs mobile service for cancer patients on chemo. News
> 'Mercenary' coders crowd-sourced for immunology research software. Report
> Biotech, pharma warming up to Facebook. Article
> Eli Lilly's virtual unit taps Oracle software for clinical trials. Story